Protalix BioTherapeutics Receives Approval to Initiate Phase I Study in Gaucher patients with PRX-112, an Orally-Administered Candidate for the Treatment of Gaucher Disease

BioTherapeutics Receives Approval to Initiate Phase I Study in Gaucher patients

with PRX-112, an Orally-Administered Candidate for the Treatment of Gaucher Disease

Israel, March 7, 2013 /GlobeNewswire /Protalix BioTherapeutics, Inc. (NYSE MKT:PLX, TASE:PLX), announced today that it has received

approval from the Israeli Ministry of Health to initiate a phase I clinical trial of PRX-112, or Oral GCD, the Company's orally-administered

product candidate for the treatment of Gaucher disease. Oral GCD is a plant cell expressed form of the glucocerebrosidase enzyme

(GCD) that is naturally encapsulated within carrot cells and administered orally. The Company anticipates initiating this trial

in two Israeli medical centers during the next month.

majority of currently diagnosed patients with Gaucher disease are treated with bi-weekly intravenous infusions of enzyme replacement

therapy. Having a safe and effective orally available enzyme agent would potentially improve patients' quality of life without

compromising on the benefits of enzyme therapy," commented Dr. David Aviezer, Protalix BioTherapeutics' President and Chief

Executive Officer. "Our clinical trial programs for IV administered plant cell-expressed GCD have already demonstrated that

the enzyme is safe and effective in treating Gaucher disease. Now, in evaluating Oral GCD, our main goal is to achieve therapeutic

levels of the enzyme in the bloodstream after oral consumption by patients."

phase I clinical trial is an open label safety and pharmacokinetic study designed to assess the delivery of prGCD after oral administration

of Oral GCD in 12 Gaucher patients. Subjects will receive 250mL of re-suspended carrot cells in a single oral administration during

the first cohort of the trial and three consecutive daily administrations during the second cohort of the trial. The Company expects

the phase I trial to be completed during the second quarter of 2013.

studies of oral GCD demonstrate the stability of the enzyme in the carrot cell and the capacity of the cell's cellulose wall to

protect the enzyme against degradation in the digestive tract in an in-vitro model of the stomach and intestines. Additionally,

both rats and pigs fed with PRX 112, lyophilized carrot cells expressing GCD, have demonstrated enzyme levels in the plasma and

accumulation of the active enzyme in target organs such as the spleen and liver.

Dr. Yoseph Shaaltiel, Protalix BioTherapeutics' Executive Vice

President, Research & Development added: "Our animal studies have already demonstrated the capacity of plant cells to

serve as a vehicle for oral administration of other therapeutic proteins. These proteins include for example, our plant cell-expressed

antiTNF fusion protein, a plant cell version of etanercept (Enbrel ). Given the results of our preclinical studies, we believe

our Oral GCD clinical study will support our belief that we have developed a wider platform for oral protein delivery."

Protalix is a biopharmaceutical company focused on the development

and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell based expression system,

ProCellEx . Protalix's unique expression system presents a proprietary method for developing recombinant proteins in a cost-effective,

industrial-scale manner. Protalix's first product manufactured by ProCellEx, ELELYSO (taliglucerase alfa), was approved

for marketing by the U.S. Food and Drug Administration on May 1, 2012 and by Israel's Ministry of Health in September 2012. Protalix

has partnered with Pfizer Inc. for the worldwide development and commercialization of ELELYSO , excluding Israel, where Protalix

retains full rights. Marketing applications for taliglucerase alfa have been filed in additional territories as well. Protalix's

development pipeline also includes the following product candidates: PRX-102, a modified version of the recombinant human alpha-GAL-A

protein for the treatment of Fabry disease; PRX-105, a pegylated recombinant human acetylcholinesterase in development for several

therapeutic and prophylactic indications, a biodefense program and an organophosphate-based pesticide treatment program; an orally-delivered

glucocerebrosidase enzyme that is naturally encased in carrot cells, also for the treatment of Gaucher disease; pr-antiTNF, a similar

plant cell version of etanercept (Enbrel ) for the treatment of certain immune diseases such as rheumatoid arthritis, juvenile

idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis and plaque psoriasis; and others.

Forward Looking Statements

To the extent that statements in this press release are not

strictly historical, all such statements are forward-looking, and are made pursuant to the safe-harbor provisions of the Private

Securities Litigation Reform Act of 1995. The terms "anticipate," "believe," "estimate," "expect,"

"plan" and "intend" and other words or phrases of similar import are intended to identify forward-looking statements.

These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual future experience

and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as

to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause material differences

include, among others: failure or delay in the commencement or completion of our clinical trials which may be caused by several

factors, including: unforeseen safety issues; determination of dosing issues; lack of effectiveness during clinical trials; slower

than expected rates of patient recruitment; inability to monitor patients adequately during or after treatment; inability or unwillingness

of medical investigators and institutional review boards to follow our clinical protocols; and lack of sufficient funding to finance

the clinical trials; the risk that the results of the clinical trials of our product candidates will not support our claims of

safety or efficacy, that our product candidates will not have the desired effects or will be associated with undesirable side effects

or other unexpected characteristics; our dependence on performance by third party providers of services and supplies, including

without limitation, clinical trial services; delays in our preparation and filing of applications for regulatory approval; delays

in the approval or potential rejection of any applications we file with the U.S. Food and Drug Administration, or other health

regulatory authorities; the inherent risks and uncertainties in developing drug platforms and products of the type we are developing;

the impact of development of competing therapies and/or technologies by other companies and institutions; potential product liability

risks, and risks of securing adequate levels of product liability and clinical trial insurance coverage; and other factors described

in our filings with the U.S. Securities and Exchange Commission. The statements in this release are valid only as of the date hereof

and we disclaim any obligation to update this information.

The Trout Group, LLC

MacDougall Biomedical Communications

Source: Protalix BioTherapeutics, Inc.